Trials / Completed
CompletedNCT05069831
JAK Inhibition in Food Allergy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abrocitinib | Abrocitinib daily for 4 months |
Timeline
- Start date
- 2022-05-16
- Primary completion
- 2025-06-13
- Completion
- 2025-06-13
- First posted
- 2021-10-06
- Last updated
- 2025-07-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05069831. Inclusion in this directory is not an endorsement.